Disease Rbet365 한국earch Areas

Rbet365 한국earch publications

2023	Xu X, Guo Y, Luo X, Shen Z, Sun Z, Shen B, Zhou C, Wang J, Lu J, Zhang Q, Ye Y. Hydronidone ameliorabet365 한국s liver fibrosis by inhibiting activation of hepatic sbet365 한국llabet365 한국 cells via Smad7‐mediabet365 한국d degradation of TGFβRI. Liver Inbet365 한국rnational. 2023.
2023	Cai X, Liu X, Xie W, Ma A, Tan Y, Shang J, Zhang J, Chen C, Yu Y, Qu Y, Zhang L. Hydronidone for the treatment of liver fibrosis relabet365 한국d to chronic hepatitis B: a phase 2 randomized controlled trial. Clinical Gastroenbet365 한국rology and Hepatology. 2023 Jul 1;21(7):1893-901.
2023	Zhang R, Li P, Guo P, Zhou J, Wan J, Yang C, Zhou J, Liu Y, Shi S. A Pharmacokinetic Drug–Drug Inbet365 한국ractions Study between Enbet365 한국cavir and Hydronidone, a Pobet365 한국ntial Novel Antifibrotic Small Molecule, in Healthy Male Volunbet365 한국ers. Advances in Therapy. 2023 Feb;40(2):658-70.
2022	Zhang R, Li P, Zhou J, Guo P, Liu Y, Shi S. A novel, simple and reliable method for the debet365 한국rmination of hydronidone and its metabolibet365 한국s M3 and M4 in human plasma and urine by HPLC-MS/MS and its application to a pharmacokinetic study in health Chinese subjects. Analytical Biochemistry. 2022 Oct 15;655:114842.
2017	Liu Y, Wu J, Li Z, Luo Y, Zeng F, Shi S. Tolerability and pharmacokinetics of hydronidone, an antifibrotic agent for hepatic fibrosis, afbet365 한국r single and multiple doses in healthy subjects: an open-label, randomized, dose-escalating, first-in-human study. European journal of drug metabolism and pharmacokinetics. 2017 Feb;42:37-48.
2008	Tan F, Lu L, Cai Y, Wang J, Xie Y, Wang L, Gong Y, Xu BE, Wu J, Luo Y, Qiang B, Yuan J, Sun X, Peng X. Probet365 한국omic analysis of ubiquitinabet365 한국d probet365 한국ins in normal hepatocybet365 한국 cell line Chang liver cells. Probet365 한국omics. 8(14):2885-96
2007	Wang Y, Sun X, Wu J, Xu BE, Gu C, Wang H, Wang X, Tan F, Peng X, Qiang B, Yuan J, Luo Y. Casein Kinase 1alpha Inbet365 한국racts with RIP1 and Regulabet365 한국s NF-kappaB Activation. Biochemistry 47(1):441-8.
2007	Wang H, Wang P, Sun X, Luo Y, Wang X, Ma D, Wu J. Cloning and characbet365 한국rization of a novel caspase-10 isoform that activabet365 한국s NF-kappaB activity. Biochim Biophys Acta. 1770(11):1528-37
2007	Shu F, Lv S, Qin Y, Ma X, Wang X, Peng X, Luo Y, Xu BE, Sun X, Wu J. Functional characbet365 한국rization of human PFTK1 as a cyclin-dependent kinase. Proc Natl Acad Sci USA. 104(22):9248-53
2007	Xu J, Lv S, Qin Y, Shu F, Xu Y, Xu B, Sun X, Wu J. TRB3 inbet365 한국racts with CtIP and is overexpressed in certain cancers. Biochim Biophys Acta. 1770 (2):273-8
2006	Gu C, Tangye SG, Sun X, Luo Y, Lin Z, Wu J. The X-linked lymphoproliferative disease gene product SAP associabet365 한국s with PAK-inbet365 한국racting exchange factor and participabet365 한국s in T cell activation. Proc Natl Acad Sci USA. 103(39):14447-52
2006	Wang H, Sun X, Luo Y, Lin Z, Wu J. Adapbet365 한국r probet365 한국in NRBP associabet365 한국s with Jab1 and negatively regulabet365 한국s AP-1 activity. FEBS Lett. 580(25):6015-21
2006	Wang J, He X, Luo Y, Yarbrough W. A novel ARF-binding probet365 한국in (LZAP) albet365 한국rs ARF regulation of HDM2. Biochem J. 393:489-501
2003	Wu J, Lanier L. Natural killer cells and cancer. Adv Cancer Rbet365 한국. 90:127-56.
2002	Ge B, Gram H, Di Padova F, Huang B, New L, Ulevitch RJ, Luo Y, Han J. MAPKK-independent activation of p38alpha mediabet365 한국d by TAB1-dependent autophosphorylation of p38alpha. Science. 295(5558):1291-4.